Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Opioid-Induced Constipation
Interventions: Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 77
States / cities: Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more

Conditions: Cerebral Palsy, CP, Spastic Cerebral Palsy
Interventions: Autologous UCB Reinfusion, Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 12 Months to 6 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19
Interventions: Lenzilumab, Placebo, Remdesivir; Biological · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo; Drug
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Hypogonadism, Male, Fatigue Syndrome, Chronic
Interventions: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo; Drug · Other
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 54 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 38
States / cities: Birmingham, Alabama • Bakersfield, California • Cerritos, California + 33 more

Conditions: PTSD, Alcohol Use Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: Deferiprone oral solution, Placebo; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 4 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Frailty
Interventions: Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: MA-0211, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions: Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg; Drug
Lead sponsor: Karen Klahr Miller, MD; Other
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 57
States / cities: Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions: Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide); Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01, Placebo; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more

Conditions: Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pain
Interventions: clonidine, adenosine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Bipolar Disorder
Interventions: emotion recognition modification - sad>happy, emotion recognition modification - sad>happy control, emotion recognition modification - angry>happy, emotion recognition modification - angry>happy control; Other
Lead sponsor: Northwell Health; Other
Eligibility: 16 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Intestinal Multi-drug Resistant Organism Colonization
Interventions: Microbiome Therapeutic, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Friedreich's Ataxia
Interventions: RT001, Placebo; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more

Conditions: Degenerative Arthritis and Postoperative Pain
Interventions: Placebo, Gapabentin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions: Oxybutynin Chloride IR, Mirabegron; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Obesity
Interventions: Alcohol challenge test Alcohol visit first, Alcohol challenge test Placebo visit first; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anaheim, California • Chula Vista, California • South Miami, Florida

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Search by objective public record fields.

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Ghrelin in Healthy and Frail Older Women

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Efficacy and Safety of VDPHL01 in Males With AGA

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

Clonidine Versus Adenosine to Treat Neuropathic Pain

Emotion Recognition Modification for Bipolar Disorder

Further MT for Antibiotic-Resistant Bacterial Colonization

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Effect of Gabapentin on Orthopedic Pain

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

Effects of Alcohol After Bariatric Surgery

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Study to Examine the Effects of Oral Fenretinide